|
|
 |
|
Viewing report
|
|
|
|
South Africa Pharmaceuticals and Healthcare Report Q3 2007
Business Monitor International, Oct 2007, Pages: 76
The South Africa Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on South Africas pharmaceuticals and healthcare industry.
South Africa has one of the most developed pharmaceutical markets in the Middle East and Africa (MEA) region - only Turkey’s market is larger. Pharmaceutical spending was US$3.08bn in 2006, and we forecast this will rise to US$4.62bn by 2011.
Market growth will be hampered by a series of cost-containment measures introduced by the government. Authorities plans to draw up a National Health Reference Price List, which will increase transparency in the private health sector. However, many in the industry see this as a way for the government to exert downward pressure on pharmaceutical prices.
Demand for antiretrovirals (ARVs) will remain high due to the country’s position at the centre of Africa’s HIV/AIDS pandemic. However, funding for drugs will remain a problem, since the majority of patients have low incomes, so are reliant on state-healthcare.
The government is due to announce a new ARV tender in Q108, something that has already seen local manufacturers jockeying for position. Rapidly growing Enaleni Pharmaceuticals will be hoping for a large slice of the contract. As will Adcock Ingram - in the process of being decoupled from the Tiger Brands Group - which launched its own range of branded-generic ARVs earlier this year.
South Africa became the first developing country to join the Pharmaceutical Inspection Convention and Co-operation Scheme (PIC/S) in July, which sets out stringent good manufacturing practice (GMP) guidelines. Most multinationals operating in South Africa already comply with the scheme. However, a number of local drug makers, including Enaleni are not yet up to standard. Enaleni chose to close its main manufacturing plant for two months between July and September to speed up the upgrade.
South Africa remains in joint sixth position in the updated MEA Business Environment Rankings for Q307. The country benefits from a relatively stable political climate and large market size. However, its limited potential for growth, and strong domestic manufacturing sector, which includes Aspen Pharmacare, one of the world’s top-20 generic manufacturers, serve to hold down the market’s score.
Customers who bought this item also bought
South Africa Pharmaceuticals and Healthcare Report Q1 2008
South Africa Pharmaceuticals and Healthcare Report Q3 2008
South Africa Pharmaceuticals and Healthcare Report Q4 2009
The Pharmaceutical Market: South Africa
South Africa Pharmaceuticals and Healthcare Report Q4 2008
Analgesics in South Africa
Eye Care in South Africa
Wound Treatments in South Africa
South Africa Pharmaceuticals and Healthcare Report Q1 2009
Pharmaceutical Industry in South Africa
Vitamins and Dietary Supplements in South Africa
Medicated Skin Care in South Africa
|
|
|
|
